Search Results - "Posey, Avery D."

Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability by Guedan, Sonia, Madar, Aviv, Casado-Medrano, Victoria, Shaw, Carolyn, Wing, Anna, Liu, Fang, Young, Regina M, June, Carl H, Posey, Jr, Avery D

“…Chimeric antigen receptor-T (CAR-T) cell therapies can eliminate relapsed and refractory tumors, but the durability of antitumor activity requires in vivo…”
Get full text

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology by Watanabe, Keisuke, Kuramitsu, Shunichiro, Posey, Jr, Avery D, June, Carl H

“…A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the lack of truly tumor-specific target antigens, which translates to…”
Get full text

Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity by Sosnoski, Heather M, Posey, Jr, Avery D

“…Anti-CD19 CAR T cells were among the last decade's scientific breakthroughs, achieving remarkable remissions in patients with B cell leukemias and lymphomas…”
Get more information

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma by Posey, Avery D., Schwab, Robert D., Boesteanu, Alina C., Steentoft, Catharina, Mandel, Ulla, Engels, Boris, Stone, Jennifer D., Madsen, Thomas D., Schreiber, Karin, Haines, Kathleen M., Cogdill, Alexandria P., Chen, Taylor J., Song, Decheng, Scholler, John, Kranz, David M., Feldman, Michael D., Young, Regina, Keith, Brian, Schreiber, Hans, Clausen, Henrik, Johnson, Laura A., June, Carl H.

“…Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate robust responses against lineage restricted, non-essential targets in…”
Get full text

Forks in the road for CAR T and CAR NK cell cancer therapies by Dagher, Oula K., Posey, Avery D.

“…The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented long-term clearance of relapse/refractory hematological malignancies…”
Get full text

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells by Guedan, Sonia, Chen, Xi, Madar, Aviv, Carpenito, Carmine, McGettigan, Shannon E., Frigault, Matthew J., Lee, Jihyun, Posey, Avery D., Scholler, John, Scholler, Nathalie, Bonneau, Richard, June, Carl H.

“…With the notable exception of B-cell malignancies, the efficacy of chimeric antigen receptor (CAR) T cells has been limited, and CAR T cells have not been…”
Get full text

Driving cars to the clinic for solid tumors by Castellarin, Mauro, Watanabe, Keisuke, June, Carl H., Kloss, Christopher C., Posey, Avery D.

“…FDA approval of chimeric antigen receptor T cells (CART cells) is the culmination of several decades of technology development and interrogation of the…”
Get full text

Advances in cancer immunotherapies by Dagher, Oula K., Schwab, Robert D., Brookens, Shawna K., Posey, Avery D.

“…Therapeutic modalities that engage the immune system to recognize and eliminate cancer, known as cancer immunotherapy, has emerged as a distinct pillar of…”
Get full text

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies by Parker, Kevin R., Migliorini, Denis, Perkey, Eric, Yost, Kathryn E., Bhaduri, Aparna, Bagga, Puneet, Haris, Mohammad, Wilson, Neil E., Liu, Fang, Gabunia, Khatuna, Scholler, John, Montine, Thomas J., Bhoj, Vijay G., Reddy, Ravinder, Mohan, Suyash, Maillard, Ivan, Kriegstein, Arnold R., June, Carl H., Chang, Howard Y., Posey, Avery D., Satpathy, Ansuman T.

“…CD19-directed immunotherapies are clinically effective for treating B cell malignancies but also cause a high incidence of neurotoxicity. A subset of patients…”
Get full text

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells by Kawalekar, Omkar U., O’Connor, Roddy S., Fraietta, Joseph A., Guo, Lili, McGettigan, Shannon E., Posey, Avery D., Patel, Prachi R., Guedan, Sonia, Scholler, John, Keith, Brian, Snyder, Nathaniel W., Blair, Ian A., Milone, Michael C., June, Carl H.

“…Chimeric antigen receptors (CARs) redirect T cell cytotoxicity against cancer cells, providing a promising approach to cancer immunotherapy. Despite extensive…”
Get full text

Expression of inducible factors reprograms CAR-T cells for enhanced function and safety by Smole, Anže, Benton, Alexander, Poussin, Mathilde A., Eiva, Monika A., Mezzanotte, Claudia, Camisa, Barbara, Greco, Beatrice, Sharma, Prannda, Minutolo, Nicholas G., Gray, Falon, Bear, Adham S., Baroja, Miren L., Cummins, Casey, Xu, Chong, Sanvito, Francesca, Goldgewicht, Andrea Lang, Blanchard, Tatiana, Rodriguez-Garcia, Alba, Klichinsky, Michael, Bonini, Chiara, June, Carl H., Posey, Avery D., Linette, Gerald P., Carreno, Beatriz M., Casucci, Monica, Powell, Daniel J.

“…Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety remain. Investigators have begun to enhance CAR-T cells with the…”
Get full text

Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety by Posey, Avery D., Clausen, Henrik, June, Carl H.

“…Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent clinical antitumor effects in a variety of blood cancers. However,…”
Get full text

Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell–Intrinsic, T Cell–Extrinsic, and Therapeutic Limitations by Brookens, Shawna K., Posey, Avery D.

“…Genetically engineered chimeric antigen receptor (CAR) T-cell therapy leverages the ability of the immune system to eliminate tumors and redirects cytotoxic…”
Get full text

Sweet Immune Checkpoint Targets to Enhance T Cell Therapy by Derosiers, Nohelly, Aguilar, William, DeGaramo, David A, Posey, Jr, Avery D

“…Despite tremendous success against hematological malignancies, the performance of chimeric Ag receptor T cells against solid tumors remains poor. In such…”
Get full text

Glycan-directed CAR-T cells by Steentoft, Catharina, Migliorini, Denis, King, Tiffany R, Mandel, Ulla, June, Carl H, Posey, Jr, Avery D

“…Cancer immunotherapy is rapidly advancing in the treatment of a variety of hematopoietic cancers, including pediatric acute lymphoblastic leukemia and diffuse…”
Get full text

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting by Bear, Adham S., Blanchard, Tatiana, Cesare, Joseph, Ford, Michael J., Richman, Lee P., Xu, Chong, Baroja, Miren L., McCuaig, Sarah, Costeas, Christina, Gabunia, Khatuna, Scholler, John, Posey, Avery D., O’Hara, Mark H., Smole, Anze, Powell, Daniel J., Garcia, Benjamin A., Vonderheide, Robert H., Linette, Gerald P., Carreno, Beatriz M.

“…Activating RAS missense mutations are among the most prevalent genomic alterations observed in human cancers and drive oncogenesis in the three most lethal…”
Get full text

CAR T-Cell Therapies in Glioblastoma: A First Look by Migliorini, Denis, Dietrich, Pierre-Yves, Stupp, Roger, Linette, Gerald P, Posey, Jr, Avery D, June, Carl H

“…Glioblastoma is an aggressive malignancy with a poor prognosis. The current standard of care for newly diagnosed glioblastoma patients includes surgery to the…”
Get full text

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager by Wing, Anna, Fajardo, Carlos Alberto, Posey, Jr, Avery D, Shaw, Carolyn, Da, Tong, Young, Regina M, Alemany, Ramon, June, Carl H, Guedan, Sonia

“…T cells expressing chimeric antigen receptors (CART) have shown significant promise in clinical trials to treat hematologic malignancies, but their efficacy in…”
Get more information

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma by Johnson, Laura A, Scholler, John, Ohkuri, Takayuki, Kosaka, Akemi, Patel, Prachi R, McGettigan, Shannon E, Nace, Arben K, Dentchev, Tzvete, Thekkat, Pramod, Loew, Andreas, Boesteanu, Alina C, Cogdill, Alexandria P, Chen, Taylor, Fraietta, Joseph A, Kloss, Christopher C, Posey, Jr, Avery D, Engels, Boris, Singh, Reshma, Ezell, Tucker, Idamakanti, Neeraja, Ramones, Melissa H, Li, Na, Zhou, Li, Plesa, Gabriela, Seykora, John T, Okada, Hideho, June, Carl H, Brogdon, Jennifer L, Maus, Marcela V

“…Chimeric antigen receptors (CARs) are synthetic molecules designed to redirect T cells to specific antigens. CAR-modified T cells can mediate long-term durable…”
Get more information

Engineering and Design of Chimeric Antigen Receptors by Guedan, Sonia, Calderon, Hugo, Posey, Jr, Avery D, Maus, Marcela V

“…T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in…”
Get full text